Dermata Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
DRMA$0.77+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Par Value | Capital | Deficit | Equity | |
| Balance at December 31, 2023 | 26,150 | $3 | $59,742,893 | $(53,387,878) | $6,355,018 |
| Issuance of abeyance shares | 18,200 | 2 | (2) | - | - |
| Issuance of Common Stock and warrants from May 2024 Warrant Inducement | 51,633 | 5 | 2,311,533 | - | 2,311,538 |
| Settlement of fractional shares paid in cash | (15) | - | (828) | - | (828) |
| Issuance of pre-funded warrants and warrants from September 2024 PIPE | - | - | 3,081,352 | - | 3,081,352 |
| Issuance of Common Stock upon exercise of pre-funded warrants | 100,756 | 10 | 999 | - | 1,009 |
| Issuance of Common Stock from ATM sales, net of issuance costs | 55,001 | 5 | 1,442,812 | - | 1,442,817 |
| Stock-based compensation | - | - | 657,649 | - | 657,649 |
| Net loss | - | - | - | (12,287,461) | (12,287,461) |
| Balance at December 31, 2024 | 251,725 | $25 | $67,236,408 | $(65,675,339) | $1,561,094 |
Statements of Stockholders’ Equity
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Par Value | Capital | Deficit | Equity | |
| Balance at December 31, 2024 | 251,725 | $25 | $67,236,408 | $(65,675,339) | $1,561,094 |
| Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs | 193,539 | 19 | 2,254,702 | - | 2,254,721 |
| Issuance of Common Stock upon exercise of pre-funded warrants | 97,746 | 10 | 967 | - | 977 |
| Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs | 483,447 | 48 | 5,725,668 | - | 5,725,716 |
| Settlement of fractional shares paid in cash | - | - | (367) | (367) | |
| Issuance of Common Stock and warrants from December 2025 PIPE, net of issuance costs | 1,484,312 | 149 | 3,739,540 | - | 3,739,689 |
| Issuance of Common Stock from ATM sales, net of issuance costs | 149,341 | 15 | 356,360 | - | 356,375 |
| Stock-based compensation | - | - | 143,732 | - | 143,732 |
| Net loss | - | - | - | (7,558,557) | (7,558,557) |
| Balance at December 31, 2025 | 2,660,110 | $266 | $79,457,010 | $(73,233,896) | $6,223,380 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.